Astellas Pharma Inc. Stock price

Equities

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange 01:00:00 2023-12-07 am EST Intraday chart for Astellas Pharma Inc. 5-day change 1st Jan Change
1,787 JPY -1.24% -0.06% -10.94%
Sales 2024 * 1,559B 10.77B Sales 2025 * 1,674B 11.56B Capitalization 3,244B 22.4B
Net income 2024 * 140B 968M Net income 2025 * 199B 1.37B EV / Sales 2024 *
2,37x
Net Debt 2024 * 449B 3.1B Net Debt 2025 * 317B 2.19B EV / Sales 2025 *
2,13x
P/E ratio 2024 *
23,7x
P/E ratio 2025 *
16,2x
Employees 14,484
Yield 2024 *
3,87%
Yield 2025 *
4,16%
Free-Float 98.82%
More Fundamentals * Assessed data
Dynamic Chart
US sets policy to seize government-funded drug patents if price deemed too high RE
Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer CI
Astellas, Seagen : Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review DJ
Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment MT
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy CI
China arranges for Japanese officials to visit detained Japanese citizen RE
China arranges for Japanese officials to visit detained Japanese citizen -China foreign ministry RE
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings MT
Less than 30% of Japanese firms plan China expansion - survey RE
Shopper360 Names Financial Controller MT
Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday as Treasury Yields Decline MT
Astellas Pharma Acquires Propella Therapeutics in $175M Deal, Gains Access to Innovative Oncology Drugs MT
Pfizer: FDA approval for cancer CF
Pfizer, Astellas Say Xtandi Receives FDA's Approval of Supplemental Application for Treatment of Prostate Cancer MT
Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting CI
More news
1 day-1.24%
1 week-0.58%
Current month-0.58%
1 month+0.22%
3 months-19.05%
6 months-20.93%
Current year-10.94%
More quotes
1 week
1 777.00
Extreme 1777
1 814.00
1 month
1 748.00
Extreme 1748
1 839.50
Current year
1 748.00
Extreme 1748
2 360.50
1 year
1 748.00
Extreme 1748
2 360.50
3 years
1 470.00
Extreme 1470
2 360.50
5 years
1 356.00
Extreme 1356
2 360.50
10 years
1 062.00
Extreme 1062
2 360.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 1986
Chairman 63 1986
Director of Finance/CFO 61 2022
Members of the board TitleAgeSince
Director/Board Member 66 2021
Director/Board Member 74 2017
Chief Executive Officer 61 1986
More insiders
Date Price Change Volume
23-12-07 1,787 -1.24% 6 486 200
23-12-06 1,809.5 +1.06% 5,238,500
23-12-05 1,790.5 -0.17% 5,357,400
23-12-04 1,793.5 -0.72% 5,674,500
23-12-01 1,806.5 +0.50% 4,955,600

Delayed Quote Japan Exchange, December 07, 2023 at 01:00 am EST

More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1,809.5JPY
Average target price
2,610JPY
Spread / Average Target
+44.24%
Consensus
1st Jan change Capi.
-10.94% 22 027 M $
+61.07% 530 B $
+43.20% 438 B $
-11.34% 377 B $
-4.79% 268 B $
-9.42% 258 B $
-13.34% 230 B $
+0.55% 200 B $
-9.56% 198 B $
-43.81% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Astellas Pharma Inc. - Japan Exchange
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer